Dr. Abou-Alfa on the Ongoing Impact and Role of Regorafenib in HCC

Ghassan K. Abou-Alfa, MD
Published: Wednesday, Nov 08, 2017



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Regorafenib, Abou-Alfa explains, is a unique agent that should not bee known as a "cousin" to sorafenib (Nexavar). In a study, regorafenib was compared with placebo in patients with HCC who progressed on sorafenib, which showed a 10.7-month improvement in survival.

Patients who progress on standard sorafenib will undoubtedly benefit from treatment with regorafenib, Abou-Alfa explains.

  <<< View more from the 2017 Chemotherapy Foundation Symposium


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Regorafenib, Abou-Alfa explains, is a unique agent that should not bee known as a "cousin" to sorafenib (Nexavar). In a study, regorafenib was compared with placebo in patients with HCC who progressed on sorafenib, which showed a 10.7-month improvement in survival.

Patients who progress on standard sorafenib will undoubtedly benefit from treatment with regorafenib, Abou-Alfa explains.

  <<< View more from the 2017 Chemotherapy Foundation Symposium



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x